Table 1 Baseline characteristics of the 604 AML patients.

From: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients

Female, n (%)

255 (42)

Age, median (range), y

77 (59–94)

ECOG performance status, n (%)

 ECOG 0

 ECOG 1

 ECOG 2

 ECOG 3

77 (13)

216 (36)

250 (41)

61 (10)

ELN 2017 risk classification*, n (%)

 Favorable

 Intermediate

 Adverse

 Missing data

101 (17)

124 (21)

363 (62)

16 (3)

ELN 2022 risk classification*, n (%)

 Favorable

 Intermediate

 Adverse

 Missing data

74 (13)

85 (14)

428 (73)

17 (3)

ICC 2022*, n (%)

 AML with myelodysplasia-related gene mutations

 AML with mutated TP53

 AML with mutated NPM1

 AML not otherwise specified (NOS)

 AML with myelodysplasia-related cytogenetic abnormalities

 AML with MECOM rearrangements

 AML with KMT2A rearrangements

 Core-binding factor AML

 AML with in-frame bZIP mutated CEBPA

 AML with t(9;22)(q34.1;q11.2)/BCR::ABL1

 Missing data

266 (45)

102 (17)

93 (16)

60 (10)

30 (5)

17 (3)

9 (1.5)

8 (1.4)

2 ( <1)

1 ( <1)

16 (3)

Therapy-related AML, n (%)

 Missing data, n

9 (1.5)

2

AML with myelodysplasia-related changes, n (%)

 Missing data, n

162 (27)

2

WBC, median (range) × 109/L

3.6 (0.3–216)

Platelet count, median (range) × 109/L

47 (1–1550)

Hemoglobin, median (range), g/dL

9 (3.5–17)

Peripheral blood blasts [Investigator], median (range)

 Missing data, n

11 (0–99)

0

Peripheral blood blasts [Central], median (range)

 Missing data, n

14 (0–99)

65

Bone marrow blasts [Investigator], median (range)

 Missing data, n

45 (0.8–100)

0

Bone marrow blasts [Central], median (range)

 Missing data, n

59 (1–100)

37

Treatment, n (%)

 Guadecitabine

 Azacitidine

 Decitabine

 Low-dose cytarabine

 No treatment

290 (48)

154 (25)

124 (21)

21 (3.5)

15 (2.5)

Number of cycles administered, median (range)

 Guadecitabine

 Azacitidine

 Decitabine

 Low-dose cytarabine

5 (1–38)

6 (1–31)

5 (1–31)

3 (1–18)

  1. Due to small sample sizes, distinct ICC entities are combined into one category, e.g., AML with (8;21)(q22;q22.1)/RUNX1::RUNX1T1, AML with inv(16)(p13.1q22) and t(16;16)(p13.1;q22)/CBFB::MYH11 was fused to “core-binding factor AML”, AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2, MECOM(EVI1) or t(3q26.2;v) were fused to “AML with MECOM rearrangements”.
  2. ECOG Eastern Cooperative Oncology Group, ELN European LeukemiaNet, ICC International Consensus Classification, WBC white blood cell count.
  3. * ELN 2017, ELN 2022, and ICC 2022 were evaluable in 588, 587, and 588 patients, respectively.
Back to article page